CXCL13 activation of c-Myc induces RANK ligand expression in stromal/preosteoblast cells in the oral squamous cell carcinoma tumor-bone microenvironment

Oncogene

Volumn 32, Issue 1, 2013, Pages 97-105

  Sambandam, Y ^a   Sundaram, K ^a   Liu, A ^b   Kirkwood, K L ^b   Ries, W L ^b   Reddy, S V ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

c Myc; CXCL13; oral squamous cell carcinoma; osteoblast; RANK ligand

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR5; CXCL13 CHEMOKINE; MITOGEN ACTIVATED PROTEIN KINASE 3; OSTEOCLAST DIFFERENTIATION FACTOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NFAT3;

ARTICLE; BONE; BONE MARROW; CANCER CELL; CELL CULTURE; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; DOSE RESPONSE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUTH CARCINOMA; ONCOGENE C MYC; OSTEOBLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SCREENING; SQUAMOUS CELL CARCINOMA; TUMOR MICROENVIRONMENT; UPREGULATION;

BONE AND BONES; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHEMOKINE CXCL13; CULTURE MEDIA, CONDITIONED; HUMANS; IMMUNOHISTOCHEMISTRY; MOUTH NEOPLASMS; OSTEOBLASTS; PROTO-ONCOGENE PROTEINS C-MYC; RANK LIGAND; STROMAL CELLS; TUMOR MICROENVIRONMENT;

MURINAE; MUS;

EID: 84871952717     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.24     Document Type: Article

References (44)

1. Mao L, Hong WK, Papadimitrakopoulou VA. Focus on head and neck cancer. Cancer Cell 2004; 5: 311-316.
2. Funk GF, Karnell LH, Robinson RA, Zhen WK, Trask DK, Hoffman HT. Presentation, treatment, and outcome of oral cavity cancer: A National Cancer Data Base report. Head Neck 2002; 24: 165-180.
3. Choi S, Myers JN. Molecular pathogenesis of oral squamous cell carcinoma: Implications for therapy. J Dent Res 2008; 87: 14-32.
4. Nomura T, Shibahara T, Katakura A, Matsubara S, Takano N. Establishment of a murine model of bone invasion by oral squamous cell carcinoma. Oral Oncol 2007; 43: 257-262.
5. Mishra A, Bharti AC, Varghese P, Saluja D, Das BC. Differential expression and activation of NF-kappaB family proteins during oral carcinogenesis: Role of high risk human papillomavirus infection. Int J Cancer 2006; 119: 2840-2850.
6. Uchida D, Kawamata H, Omotehara F, Nakashiro K, Kimura-Yanagawa T, Hino S et al. Role of HGF/c-met system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance. Int J Cancer 2001; 93: 489-496.
7. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999; 96: 3540-3545.
8. Deyama Y, Tei K, Yoshimura Y, Izumiyama Y, Takeyama S, Hatta M et al. Oral squamous cell carcinomas stimulate osteoclast differentiation. Oncol Rep 2008; 20: 663-668.
9. Lynch CC, Hikosaka A, Acuff HB, Martin MD, Kawai N, Singh RK et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005; 7: 485-496.
10. Jimi E, Furuta H, Matsuo K, Tominaga K, Takahashi T, Nakanishi O. The cellular and molecular mechanisms of bone invasion by oral squamous cell carcinoma. Oral Dis 2011; 17: 462-468.
11. Zlotnik A, Yoshie O. Chemokines: A new classification system and their role in immunity. Immunity 2000; 12: 121-127.
12. Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD et al. CXC chemokines in angiogenesis. J Leukoc Biol 2000; 68: 1-8.
13. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56.
14. Legler DF, Loetscher M, Roos RS, Clark-Lewis I, Baggiolini M, Moser B. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med 1998; 187: 655-660.
15. Lisignoli G, Cristino S, Toneguzzi S, Grassi F, Piacentini A, Cavallo C et al. IL1beta and TNFalpha differently modulate CXCL13 chemokine in stromal cells and osteoblasts isolated from osteoarthritis patients: Evidence of changes associated to cell maturation. Exp Gerontol 2004; 39: 659-665.
16. Singh S, Singh R, Sharma PK, Singh UP, Rai SN, Chung LW et al. Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. Cancer Lett 2009; 283: 29-35.
17. Muller A, Sonkoly E, Eulert C, Gerber PA, Kubitza R, Schirlau K et al. Chemokine receptors in head and neck cancer: Association with metastatic spread and regulation during chemotherapy. Int J Cancer 2006; 118: 2147-2157.
18. Ziober AF, Patel KR, Alawi F, Gimotty P, Weber RS, Feldman MM et al. Identification of a gene signature for rapid screening of oral squamous cell carcinoma. Clin Cancer Res 2006; 12: 5960-5971.
19. Vachani A, Nebozhyn M, Singhal S, Alila L, Wakeam E, Muschel R et al. A 10-gene classifier for distinguishing head and neck squamous cell carcinoma and lung squamous cell carcinoma. Clin Cancer Res 2007; 13: 2905-2915.
20. Yuvaraj S, Griffin AC, Sundaram K, Kirkwood KL, Norris JS, Reddy SV. A novel function of CXCL13 to stimulate RANK ligand expression in oral squamous cell carcinoma cells. Mol Cancer Res 2009; 7: 1399-1407.
21. Pandruvada SN, Yuvaraj S, Liu X, Sundaram K, Shanmugarajan S, Ries WL et al. Role of CXC chemokine ligand 13 in oral squamous cell carcinoma associated osteolysis in athymic mice. Int J Cancer 2010; 126: 2319-2329.
22. Darimont C, Avanti O, Tromvoukis Y, Vautravers-Leone P, Kurihara N, Roodman GD et al. SV40T antigen and telomerase are required to obtain immortalized human adult bone cells without loss of the differentiated phenotype. Cell Growth Differ 2002; 13: 59-67.
23. Roccisana JL, Kawanabe N, Kajiya H, Koide M, Roodman GD, Reddy SV. Functional role for heat shock factors in the transcriptional regulation of human RANK ligand gene expression in stromal/osteoblast cells. J Biol Chem 2004; 279: 10500-10507.
24. Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 2006; 107: 289-298.
25. Mikami S, Katsube K, Oya M, Ishida M, Kosaka T, Mizuno R et al. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas. J Pathol 2009; 218: 530-539.
26. Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM et al. Tumourinfiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011; 470: 548-553.
27. Lisignoli G, Toneguzzi S, Piacentini A, Cattini L, Lenti A, Tschon M et al. Human osteoblasts express functional CXC chemokine receptors 3 and 5: Activation by their ligands, CXCL10 and CXCL13, significantly induces alkaline phosphatase and beta-N-acetylhexosaminidase release. J Cell Physiol 2003; 194: 71-79.
28. El-Haibi CP, Singh R, Sharma PK, Singh S, Lillard Jr. JW. CXCL13 mediates prostate cancer cell proliferation through JNK signalling and invasion through ERK activation. Cell Prolif 2011; 44: 311-319.
29. Kikuchi T, Yoshikai Y, Miyoshi J, Katsuki M, Musikacharoen T, Mitani A et al. Cot/ Tpl2 is essential for RANKL induction by lipid A in osteoblasts. J Dent Res 2003; 82: 546-550.
30. Marampon F, Ciccarelli C, Zani BM. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors. Mol Cancer 2006; 5: 31.
31. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 2001; 79: 243-253.
32. Lee SK, Kalinowski J, Jastrzebski S, Lorenzo JA. 1,25(OH)2 vitamin D3-stimulated osteoclast formation in spleen-osteoblast cocultures is mediated in part by enhanced IL-1 alpha and receptor activator of NF-kappa B ligand production in osteoblasts. J Immunol 2002; 169: 2374-2380.
33. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: Modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 2000; 275: 768-775.
34. Kayamori K, Sakamoto K, Nakashima T, Takayanagi H, Morita K, Omura K et al. Roles of interleukin-6 and parathyroid hormone-related peptide in osteoclast formation associated with oral cancers: significance of interleukin-6 synthesized by stromal cells in response to cancer cells. Am J Pathol 2010; 176: 968-980.
35. Roux S, Mariette X. The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK ligand expression. Leuk Lymphoma 2004; 45: 1111-1118.
36. Ishikuro M, Sakamoto K, Kayamori K, Akashi T, Kanda H, Izumo T et al. Significance of the fibrous stroma in bone invasion by human gingival squamous cell carcinomas. Bone 2008; 43: 621-627.
37. Thiolloy S, Halpern J, Holt GE, Schwartz HS, Mundy GR, Matrisian LM et al. Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase- 9, contributes to tumor-induced osteolysis. Cancer Res 2009; 69: 6747-6755.
38. Wilson TJ, Nannuru KC, Futakuchi M, Sadanandam A, Singh RK. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand. Cancer Res 2008; 68: 5803-5811.
39. Perez-Sayans M, Suarez-Penaranda JM, Pilar GD, Barros-Angueira F, Gandara-Rey JM, Garcia-Garcia A. What real influence does the proto-oncogene c-myc have in OSCC behavior? Oral Oncol 2011; 47: 688-692.
40. Buchholz M, Schatz A, Wagner M, Michl P, Linhart T, Adler G et al. Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway. EMBO J 2006; 25: 3714-3724.
41. Habib T, Park H, Tsang M, de Alboran IM, Nicks A, Wilson L et al. Myc stimulates B lymphocyte differentiation and amplifies calcium signaling. J Cell Biol 2007; 179: 717-731.
42. Singh G, Singh SK, Konig A, Reutlinger K, Nye MD, Adhikary T et al. Sequential activation of NFAT and c-Myc transcription factors mediates the TGF-beta switch from a suppressor to a promoter of cancer cell proliferation. J Biol Chem 2010; 285: 27241-27250.
43. Brenner JC, Graham MP, Kumar B, Saunders LM, Kupfer R, Lyons RH et al. Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck 2010; 32: 417-426.
44. Molinolo AA, Hewitt SM, Amornphimoltham P, Keelawat S, Rangdaeng S, Meneses Garcia A et al. Dissecting the Akt/mammalian target of rapamycin signaling network: Emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 2007; 13: 4964-4973.